Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mesenchymal stromal cell transplantation for septic shock
NL-OMON26490Not yet recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2013
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Randomised, open-label trial of Provacel in septic shock and sepsis (2 arms), sponsored by Erasmus MC. Primary endpoint: Time to shock reversal. Planned start Sep 2013; status: not yet recruiting.
02
Drugs
Provacel
03
Conditions
septic shocksepsis
Beyond the preview
Go deeper on NL-OMON26490.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON26490.